Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus intravesical BCG versus BCG alone in persistent or recurrent high-risk non-muscle-invasive bladder cancer
NL-OMON50043Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bladder cancer, transitional cell carcinoma (TCC) and non-muscle-invasive bladder cancer (NMIBC) comparing Nivolumab + BCG with Placebo + BCG (2 arms). Primary endpoint: Event-free survival. Started Feb 2020; status: completed.
02
Drugs
nivolumabbcg vaccine
03
Conditions
bladder cancertransitional cell carcinoma (TCC)non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NL-OMON50043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50043.